Guidelines for the diagnosis and management of acute myeloid leukaemia in pregnancy

  title={Guidelines for the diagnosis and management of acute myeloid leukaemia in pregnancy},
  author={Sahra Ali and Gail L. Jones and Dominic Culligan and Philippa Marsden and Nigel H. Russell and Nicholas D. Embleton and Charles F Craddock},
  journal={British Journal of Haematology},
Pregnant women should be managed by a multidisciplinary team that includes haematologists, obstetricians, neonatologists and anaesthetists (Grade 1C) As for non‐pregnant patients, acute myeloid leukaemia (AML) should be diagnosed using the World Health Organization (WHO) classification (Grade 1A) Women diagnosed with AML in pregnancy should be treated without delay (Grade 1B) When the diagnosis of AML is made in the first trimester, a successful pregnancy outcome is unlikely and spontaneous… 

Acute myeloid leukaemia in pregnancy

A BCSH guideline on the management of non-acute promyelocytic leukaemia AML in pregnancy is presented, based on a thorough literature review and provides key information and recommendations to steer the patient and the multidisciplinary team (MDT) through a very difficult decision-making process.

Successful management of acute myeloid leukaemia in a twin pregnancy – a case report

This is the first report of a patient presenting with AML during a twin pregnancy who successfully underwent two cycles of chemotherapy before delivery and who wished to proceed with therapy.


  • Vina Kumari
  • Medicine
    Journal of Clinical Case Reports Medical Images and Health Sciences
  • 2022
AML during pregnancy is rare, there is no fixed protocol for and the diagnosis of leukemia in pregnancy is very difficult owing to vague presenting symptoms like fatigue and weakness which are confused with physiological changes during pregnancy.

The management of hodgkin lymphomas in pregnancies

Recommendations for managing pregnant Hodgkin lymphoma patients using three hypothetical cases and current evidence and guidelines are reviewed.

Successful molecular targeted treatment of AML in pregnancy with Azacitidine and Sorafenib with no adverse fetal outcomes

The first case of successful molecularly targeted treatment using the hypomethylating agent azacitidine with the multi-kinase inhibitor sorafenib in a pregnant woman with refractory AML resulting in no major foetal morbidity or mortality is reported.

Conservative Management of Presumed Fetal Anemia Secondary to Maternal Chemotherapy for Acute Myeloid Leukemia

Fetal MCA PSV can be used to safely and effectively screen for fetal anemia and is suggests that in the absence of hydrops fetalis or other signs of fetal decompensation, expectant management with ultrasound twice weekly, including MCAPSV, is appropriate.

A prospective registry-based cohort study of the diagnosis and management of acute leukaemia in pregnancy: Study protocol

This study is a registry-based observational cohort study which aims to monitor and record the treatment outcomes of patients diagnosed with AL during pregnancy, and establish a new research database for Leukaemia in Pregnancy.

Analysis of outcomes in hospitalized pregnant patients with acute myeloid leukemia.

The first nationwide study to document the outcomes of pregnancy in hospitalized AML patients shows that the mortality has been improving over the past 15 years and that a higher Charlson's comorbidity score was an independent predictor of mortality.

Managing Leukemia During Pregnancy

Pregnancy-associated leukemia occurs in approximately 1 in 75,000–100,000 pregnancies, and a strong recommendation for pregnancy termination, followed by initiation of induction therapy is usually not required.

New onset acute promyelocytic Leukemia during pregnancy: report of 2 cases

Physicians should pay more attention to APL during pregnancy and thus may save more maternal and fetal lives.



How I treat acute and chronic leukemia in pregnancy.

Cytotoxic therapy and pregnancy.

Hematologic malignancies in pregnancy.

Management of cancer during pregnancy.

This report will review the available data that may assist in decisions regarding the use of irradiation and chemotherapy during pregnancy and suggest the goal should shift to protection of the fetus from damage by the injudicious use of teratogenic cancer therapy.

Teratogenic effects in a case of maternal treatment for acute myelocytic leukaemia—neonatal and infantile course

The clinical phenotype and infantile development of a girl born to a 36-year-old mother with acute myelocytic leukaemia and who has had to undergo two operations for fronto-orbital advancement is reported, which is reminiscent of the Baller-Gerold syndrome.

Cancer during pregnancy: an analysis of 215 patients emphasizing the obstetrical and the neonatal outcomes.

Pregnant cancer patients should be treated in a multidisciplinary setting with access to maternal and neonatal intensive care units and prevention of iatrogenic prematurity appears to be an important part of the treatment strategy.

Anthracyclines in the treatment of malignancy in pregnancy

Two cases and twenty‐six additional cases using this class of agents to treat malignancy during pregnancy are summarized from 18 reports for a total of 28 pregnancies, resulting in 24 normal infants including a set of twins in the current report.

Acute Leukemia during Pregnancy: A Single Institutional Experience with 17 Cases

It is confirmed that pregnancy per se may not affect the outcome of chemotherapy in AML and suggested that treatment delays may compromise maternal outcome without improving pregnancy outcome.

Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.

This review contains specific recommendations for the identification and management of most important complications such as the bleeding disorder, APL differentiation syndrome, QT prolongation and other ATRA- and ATO-related toxicities, as well as for molecular assessment of response to treatment.

Long-term follow-up of children born to mothers with acute leukemia during pregnancy.

The results of this study indicate that pregnancy is not a counterindication for treatment of patients with acute leukemia, and in the cases described here chemotherapy is not associated with excessive risk to the fetus.